AJANTPHARM logo

Ajanta Pharma Limited Stock Price

NSEI:AJANTPHARM Community·₹304.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

AJANTPHARM Share Price Performance

₹2,419.00
-838.75 (-25.75%)
26.5% undervalued intrinsic discount
₹3,293.00
Fair Value
₹2,419.00
-838.75 (-25.75%)
26.5% undervalued intrinsic discount
₹3,293.00
Fair Value
Price ₹2,419.00
AnalystHighTarget ₹3,293.00
AnalystConsensusTarget ₹3,008.33
AnalystLowTarget ₹2,307.00

AJANTPHARM Community Narratives

AnalystHighTarget·
Fair Value ₹3.29k 26.5% undervalued intrinsic discount

Expanding Asian And African Markets Will Drive Secular Growth

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹3.01k 19.6% undervalued intrinsic discount

Aging Demographics And Emerging Markets Will Fuel Global Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AnalystLowTarget·
Fair Value ₹2.04k 18.3% overvalued intrinsic discount

Tightening Global Regulations And Supply Risks Will Drag Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent AJANTPHARM News & Updates

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Might Deserve Your Attention Today

Aug 18
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Might Deserve Your Attention Today

Ajanta Pharma Limited (NSE:AJANTPHARM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Ajanta Pharma Limited (NSE:AJANTPHARM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Jul 30
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

May 26
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

Mar 29
If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Feb 20
What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Ajanta Pharma Limited Key Details

₹48.1b

Revenue

₹11.5b

Cost of Revenue

₹36.5b

Gross Profit

₹27.2b

Other Expenses

₹9.3b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 03, 2025
Earnings per share (EPS)
74.46
Gross Margin
76.05%
Net Profit Margin
19.35%
Debt/Equity Ratio
1.3%

Ajanta Pharma Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet average dividend payer.

1 Risk
3 Rewards

About AJANTPHARM

Founded
1973
Employees
9628
CEO
Yogesh Agrawal
WebsiteView website
www.ajantapharma.com

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Indian Market Performance

  • 7 Days: 0.9%
  • 3 Months: 0.1%
  • 1 Year: -4.1%
  • Year to Date: 1.6%
Over the last 7 days, the market has remained flat, although notably the Information Technology sector gained 3.8% in that time. As for last year, the market is down 4.1%. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›